According to Dr. Lo, “Viral kinetics is a classic example of mathematical biology, where insights derived from modeling have had significant impact on the understanding and treatment of viral diseases that cause chronic infection. The fundamental structure of the viral kinetics model for HIV has been adapted to other diseases, such as Hepatitis B (HBV) and Hepatitis C (HCV), resulting in a broader understanding of chronic viral infection."
Dr. Lo explained that, currently, pharmaceutical companies are searching for approvable, interferon-free, combination therapies for HCV. This has led to significant investment in developing therapies with different mechanisms of action. Intense research on these new therapies has produced data from a combination of approaches, including clinical data, preclinical and clinical pharmacokinetic (PK) data, and in vitro data for comparable compounds. Thus, an opportunity has arisen for refining existing models to optimize compound selection and predicted efficacy compared to current standards of care.
Dr. Lo will describe one approach to viral kinetics modeling, where preclinical and clinical data from competitor compounds were incorporated into an existing model that included the dynamics of mutant viral strains. He will illustrate the insights derived from this modeling work, and how they improved the understanding of proprietary candidate compounds. In addition, he will demonstrate the model’s ability to differentiate between competing compounds, based on the predicted ability to reduce the viral load in patients.
Register for this free webinar at http://www.rosaandco.com/
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.